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rug-Eluting Stents and
ate Adverse Clinical Outcomes
essons Learned, Lessons Awaited*
otirios Tsimikas, MD, FACC
a Jolla, California
ndothelial cells form a continuous syncytium that sepa-
ates the intravascular and extravascular space. The endo-
helium is a selectively permeable and metabolically active
ascular component that regulates important pathophysio-
ogical processes such as hemostasis, thrombosis, and syn-
hesis of growth factors, nitric oxide, and matrix proteins.
ndothelial dysfunction is one of the earliest events in
therogenesis and is often mediated by endothelial cell
njury induced by a variety of cardiovascular risk factors.
isruption and damage of the endothelium, such as that
hich occurs during percutaneous coronary intervention,
ltimately results in a predictable regeneration of the endo-
helium. However, if the injury is excessive, prolonged, or of
nature that limits normal healing, as is clearly documented
ith brachytherapy, late clinical events will occur, albeit
ith low incidence but increasing frequency, even with dual
ntiplatelet therapy.
See page 2108
In this issue of the Journal, Kotani et al. (1) provide
obering angioscopic data on the rate of neointimal coverage
f drug-eluting stents (DES) that complement recent
athological and clinical data on the underlying potential
echanisms of late stent thrombosis (LST). They evaluated
5 patients (37 stents, 15 DES, 22 bare-metal stents
BMS]) with angioscopy at 3 to 6 months after stent
mplantation. Using a subjective grading system based on
he neointimal coverage of stent struts, they noted that all
2 BMS (100%) had complete neointimal coverage,
hereas in stark contrast only 13.3% (2 of 15) DES had
omplete coverage. Thrombus, which was not visible angio-
raphically, tended to be more common in DES and in
tents without neointimal coverage. This study is limited by
mall sample size, different BMS, lack of use of paclitaxel-
luting stents, and a relatively short follow-up period.
onetheless, the study provides mechanistic underpinnings
hrough which DES and/or their individual components
ay result in LST, defined as 30 days after stent implan-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, University of California San Diego, La Jolla,
alifornia. Dr. Tsimikas is supported in part by funds from the Donald W. Reynolds
oundation, Las Vegas, Nevada.ation, by suggesting that lack of or delayed neointimal
overage may be an etiologic factor.
NDOTHELIAL REGENERATION AND VESSEL
ALL RESPONSES AFTER STENT IMPLANTATION
he regeneration of iatrogenically denuded endothelium
as appreciated as early as the 1950s in distal aortas of
abbits and baboons (2). In these studies it was noted that
he endothelium regenerated via mitosis from the margins
f the denuded area, from the margins of small vascular
hannels within the denuded area, and from vasa vasorum.
peculation had even persisted that circulating blood cells
ere deposited into the denuded area and contributed to the
ndothelium, an observation now confirmed as the presence
f circulating endothelial progenitor cells. Subsequently it
as shown that endothelial regeneration is initiated by loss
f contact inhibition of adjacent endothelial cells. The
xtent of de-endothelialization and the speed of regenera-
ion is likely to have direct clinical relevance in mediating
dverse clinical sequelae.
Immediately after percutaneous coronary intervention in
umans, there is complete destruction of endothelial cells at
he injured site. In addition, stent struts penetrate the lipid
ore in the majority of cases and there is frequent medial
amage, conditions that are strongly associated with en-
anced inflammation and a propensity toward exaggerated
eointima formation (3). The endothelium generally regen-
rates within one to three months, providing a new barrier
o the inherently thrombogenic exposed plaque or stent
truts. Pathological studies of human BMS have shown that
he early healing phase (3 days) after percutaneous coro-
ary intervention is manifested by acute deposition of fibrin,
latelets, and acute inflammatory cells such as neutrophils,
reating in effect a thin, membranous thrombus that is
ltimately resorbed (4,5). By two weeks, a matrix-poor
eointima is formed, albeit with incomplete coverage of the
tent. By one month, enhanced extracellular matrix, along
ith increasing numbers of smooth muscle cells and fewer
hronic inflammatory cells, adds to the volume of neoin-
ima, generally completely covering the stent struts. Over six
onths, proteoglycans and matrix proteins and other prod-
cts of smooth muscle cells contribute to neointima forma-
ion, the extent of which is mediated by many clinical,
ngiographic, and intrinsic stent factors. These findings are
enerally reflected in the animal models commonly used to
ssess safety and efficacy of stents, such as the normal pig
oronary artery and hypercholesterolemic rabbit iliac artery
odels, which show patterns of healing similar to those of
umans but with a significantly faster time frame than in
uman arteries (6).
ES AND THROMBOGENICITY
oth CYPHER (Cordis, Miami Lakes, Florida) (71 to 314
g slow release sirolimus depending on stent size, 80%
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May 16, 2006:2112–5 Editorial Commenteleased within 30 days) and TAXUS (Boston Scientific,
atick, Massachusetts) (50 to 209 g slow-release pacli-
axel depending on stent size, data obtained from each
espective package insert) stents have closed cell designs and
ifferent cell geometry and strut thickness. They both
ontain cell-cycle inhibitors with different mechanisms of
ction and different nonerodable polymers (67%/33%
olyethylene-co-vinyl acetate/poly n-butyl methacrylate for
irolimus and poly(styrene-b-isobutylene-b-styrene) for
aclitaxel). Therefore, clinical sequelae may arise from the
tent material (316L stainless steel in both stents composed
f iron, nickel, and chromium), the respective drugs, or the
olymers, which will persist indefinitely in the vessel wall.
Not surprisingly, both the animal data and the few
uman pathological studies available on DES show funda-
ental differences in healing compared with BMS. For
xample, animals treated with BMS uniformly show com-
lete endothelialization by 28 days, whereas animals treated
ith DES uniformly show a dose-dependent delay in
ealing, manifested by persistence of fibrin around stent
truts, delayed endothelialization, and the presence of in-
ammatory cells (7–9). This lack of healing persists and may
ven be accentuated at longer time points, such as 180 days,
time point not routinely studied or previously required in
tudies with BMS before human clinical trials. Interestingly,
nimal models seem to reflect safety more specifically rather
han efficacy of various stent designs, and a catch-up
henomenon in neointima formation over three to six
onths has been noted with sirolimus, paclitaxel, and
acrolimus, so that no significant differences in efficacy are
een between BMS and DES (7–9). These findings have led
ome investigators to suggest that DES efficacy in humans
ay ultimately be short-lived, but that four to five years of
linical follow-up may be required for certainty because of
he temporal differences in efficacy in animal models versus
umans (10). Interestingly, despite these concerns, there is
significant discrepancy in efficacy parameters between
nimal data and clinical results.
However, the more serious concern is not necessarily the
otential for late catch-up phenomena, which would gen-
rally present as late restenosis and repeat target lesion
evascularization, but late stent thrombosis, which would
resent as sudden death or large myocardial infarction.
YPERSENSITIVITY REACTIONS AND DES
irmani et al. (11) initially documented a localized hyper-
ensitivity reaction in a 58-year-old man who died 18
onths after CYPHER stent implantation, consisting of
ragments of polymer, T-cells, and eosinophils. They im-
licated the nonerodable polymer, because sirolimus is no
onger present in the vessel wall after 60 days and because it
as inherent anti-inflammatory properties that would sup-
ress accumulation of such inflammatory cells. Additional
ata for both systemic (rash, itching, fever, arthralgia, and so
n) and localized (eosinophilic peri-stent infiltrates) hyper- wensitivity reactions were shown by the Research on Adverse
rug Events and Reports (RADAR) project, which con-
luded that 17 definite or highly likely hypersensitivity cases
ccurred out of 262 reports potentially associated with DES
12). Four of these 17 cases were accompanied by autopsy
ata confirming the presence of peri-stent eosinophilic
nfiltrates. Interestingly, in autopsy series of BMS, no local
ypersensitivity reactions were noted in over 400 cases (13).
owever, in-stent restenosis has been associated with aller-
ies to nickel (stent component) and molybdenum (stent
mpurity) (14).
ESSONS LEARNED FROM
AILED CLINICAL TRIALS OF DES
t is now clear that both the type of drug and the dose are
ritically important in determining efficacy and adverse events
15). For example, in the Actinomycin-eluting stent Improves
utcomes by reducing Neointima hyperplasia (ACTION)
rial, a first-look subset analysis of 39 of 240 patients
howed a significantly higher rate of target lesion revascu-
arization (TLR) with actinomycin-D compared with a
omparable BMS (16), necessitating early termination of
he trial. The rationale for any potential clinical usefulness
f this stent-drug combination was based on 28-day animal
ata, which apparently had shown both safety and efficacy.
owever, as the investigators note in the discussion of that
tudy, unpublished animal data after the trial was initiated
howed that the polymer was safe at 180 days but that all
oses of actinomycin-D resulted in medial thinning, necro-
is, fibrin deposition, and inflammation, all signposts of
oor vessel healing (16). Similarly, the Study to Compare
estenosis Rates between Quest and QuaDDS-QP2
SCORE) showed that 7-hexanoyltaxol, a paclitaxel deriv-
tive loaded on four to six acrylate polymer sleeves (each
.4-mm sleeve is loaded with 800-g 7-hexanoyltaxol,
otaling over 4,000 g drug per stent, compared with 110
g paclitaxel on the TAXUS stent), was associated with
ncreased stent thrombosis (3.2% vs. 0% at 1 month, 7.1%
s. 0.7% at 6 months, and 10.3% vs. 0.7% at 12 months) and
eath/myocardial infarction rates (11.9% vs. 2.1% at 1
onth, 15.9% vs. 2.1% at 6 months, and 19.0% vs. 2.1% at
2 months) (17). Unpublished data from porcine models
urportedly obtained after SCORE enrollment showed in-
ense inflammation, granulomas, fibrosis with severe nar-
owing, and occlusion in vessels stented with the QuaDDS
tent or polymer-only sleeves (17). Pathological specimens
rom atherectomy specimens derived from in-stent restenosis
atients in this trial showed persistent fibrin, extensive
roteoglycan matrix, and incomplete healing (18).
The underlying reasons for this haste to bring DES to
linical trials can be debated and may be obvious to many.
dditionally, the previously accepted standard for BMS
afety was the 28-day stent animal models. Unfortunately,
he potential for long-term adverse sequelae in these studies
as not anticipated by regulatory bodies, sponsors, or
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Editorial Comment May 16, 2006:2112–5nvestigators. The investigators and sponsors are to be
ommended for detecting these problems early, stopping
he trials, and publishing these results, which hopefully will
ead to improved scientific validation of preclinical data
efore clinical trials. One of the key lessons of these DES
xperimental studies, aside from the uncertainty of translat-
ng efficacy animal data to humans, a lesson clearly learned
rom the failure of multiple agents to prevent restenosis in
umans, is that safety animal data at 28 days does not
ecessarily predict long-term results and that longer time
oints in animals are needed before approval of such devices
or clinical trials.
LINICAL TRIALS AND LATE ADVERSE EVENTS
linical efficacy. Contrary to that in animal models and
he brachytherapy experience in humans, the current clinical
ata, although limited, do not suggest a catch-up phenom-
non. For example, in the First-in-Man study, serial quan-
itative intravascular ultrasounds obtained up to four years in
3 event-free patients treated with CYPHER stents showed
o significant further increase in neointima formation be-
ween two and four years (19). Similarly, there is a durable
fficacy in the Randomized Study with the Sirolimus-
oated Bx Velocity Balloon-Expandable Stent in the Treat-
ent of Patients with de novo Native Coronary Artery
esions (RAVEL) with three-year follow-up (20), and
wo-year follow-up in Sirolimus-Eluting Stent in de Novo
ative Coronary Lesions (SIRIUS) study (21) and the
apamycin-Eluting Stent Evaluated at Rotterdam Cardiol-
gy Hospital (RESEARCH) registry (22). Meta-analyses
f the randomized clinical trials also have not shown an
ncreased risk of adverse events related to DES (23,24).
dverse events. However, case reports and observational
tudies are increasingly reporting a definite increase, albeit
mall, in the incidence of LST, particularly during clopi-
ogrel withdrawal (25–27). For example, McFadden et al.
26) reported four cases of LST approximately one year after
ES placement, all associated with antiplatelet therapy
ithdrawal. Ong et al. (27) reported an incidence of LST of
.35% superimposed on an incidence of 1.0% in the first 30
ays. In the largest observational study that clearly reflects
eal-world findings in which off-label use was common in
ore difficult lesions and in higher-risk patients, Iakovou et
l. (25) reported a 30-day incidence of 0.6% and an LST
ncidence of 0.7%. In these observational studies, one can
ssume that these are the minimum rates, because it is likely
hat some cases are missed because of a lack of follow-up or
ecause of clinically silent stent thromboses. A uniformly
ndependent predictor of LST is antiplatelet therapy with-
rawal, either clopidogrel or both aspirin and clopidogrel, as
ell as diabetes, increased stent length, bifurcation lesions,
nd crush stenting, in which the overall stent thrombosis
ate approaches 5% (28).
Further confirmation of the specific role of DES versus
MS in stent thrombosis was recently provided by Rodriguez pt al. (29) from the Argentine Randomized Trial of Coronary
tents versus Bypass Surgery (ERACI III). They showed a
.1% (7 of 225) incidence of stent thrombosis during 18.3 
.8 months of follow-up with four cases after 30 days of stent
mplantation. Consistent with previous reports, six of seven
ases (86%) were associated with discontinuation of clopi-
ogrel. Both CYPHER and TAXUS stents had a similar
ncidence of stent thrombosis (1.9% vs. 1.5%, respectively). Of
ignificant interest, of the four patients that had multistent
lacement and concomitant DES and BMS in different
rteries, all of the stent thromboses occurred at DES sites,
trongly implicating stent-specific etiologies in LST. These
ata are further supported by the fact that DES are associated
ith paradoxical vasoconstriction at the proximal and distal
dges of stents 6 months after implantation, whereas BMS
re not associated with this phenomenon (30). Late stent
hrombosis in BMS also occurs and is likely underappreciated,
lthough it does not seem to have a similar incidence, partic-
larly because many of the DES stent thromboses occur during
lopidogrel withdrawal. Farb et al. (4) reported that LST in
MS, aside from the obvious exposure to brachytherapy, is also
ssociated with stenting across the ostia of major arterial
ranches; plaque disruption in the non-stented arterial seg-
ent within 2 mm of the stent margin; stenting of markedly
ecrotic, lipid-rich plaques with extensive plaque prolapse; and
n diffuse in-stent restenosis.
linical implications. As with all things that seem too good
o be true, there is a bit of forced reality emerging regarding the
linical usefulness of DES. Long-term follow-up of random-
zed clinical trials and registries continues to show a relative
enefit of DES over BMS and no overall higher risk of major
yocardial infarction or death. However, most of this benefit
s attributable to reduced TLR, an end point that is accentu-
ted in favor of DES by the oculostenotic reflex that invariably
s associated with mandatory angiographic follow-up. Al-
hough the morbidity of increased TLR affects patients in a
angible way and is clearly reflected by their desire to avoid
epeat procedures, selected patients, such as those who cannot
olerate or have a real possibility of needing to be withdrawn
rom clopidogrel, and their physicians, may be trading a mean
0% to 15% absolute benefit in reduced TLR for a mean 0.5%
o 2% absolute risk of LST, with LST being a much higher
orbid event often associated with death and major myocar-
ial infarction. Of course, in those who are withdrawn from
lopidogrel, the risk is much higher but difficult to quantitate,
ecause reports of large numbers of patients with clopidogrel
ithdrawal and the associated risk of LST have not been
eported.
Therefore, a reassessment of the universal use of DES, at
east in their current formulations, may be on the horizon and
hould lead to a scholarly debate regarding the optimal indi-
ations of DES. Clearly, in patients at risk for aspirin/
lopidogrel withdrawal, such as patients who generally do not
olerate many medications, those who may require elective
urgery, and those with a history of bleeding disorders, such as
rior gastrointestinal bleeding, one would have to weigh the
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May 16, 2006:2112–5 Editorial Commentisks and benefits carefully before using a DES. For example, in
nondiabetic patient with a discrete lesion in a large vessel, one
ay predict a very small absolute benefit of using a DES.
ecause it is generally difficult to predict when patients may
equire aspirin or clopidogrel withdrawal, this strategy may
ecome more common if the issue of LST persists.
As occurs with many new clinical advances, the initial
xuberance generally gives way to the realities presented by
eal-world findings, particularly as indications expand be-
ond the package insert and a reassessment occurs regarding
he optimal indications. As we move beyond the euphoria of
uring restenosis, we now must address the issues of
argeted use of DES; optimal duration of antiplatelet
herapies and novel stent/polymer designs, such as erodable,
oninflammatory polymers or no polymers whatsoever (31);
nhancement of endothelial cell coverage (32); reduction of
eri-stent inflammation; and hypersensitivity stimuli. Al-
hough the goal of curing restenosis is close at hand, we now
ust strive to bring long-term safety and efficacy to new
rontiers. The interventional community and our patients
hould expect nothing less than continued success in our
nparalleled achievements in treating cardiovascular disease.
eprint requests and correspondence: Dr. Sotirios Tsimikas,
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